Gsa Capital Partners LLP Neu Base Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $913,062 - $1.47 Million	-351,178 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.27 - $4.76 $16,438 - $23,928	5,027 Added 1.45%	351,178 $1.27 Million
Q2 2021 Aug 05, 2021	BUY	$4.63 - $7.34 $1.32 Million - $2.09 Million	284,988 Added 465.95%	346,151 $1.66 Million
Q1 2021 May 10, 2021	SELL	$6.92 - $12.36 $416,763 - $744,393	-60,226 Reduced 49.61%	61,163 $452,000
Q4 2020 Feb 03, 2021	BUY	$6.92 - $9.25 $171,636 - $229,427	24,803 Added 25.68%	121,389 $849,000
Q3 2020 Nov 06, 2020	BUY	$7.25 - $9.71 $700,248 - $937,850	96,586 New	96,586 $733,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.